LIPID INCODE
LIVE

Serial Number

79186567

Owner

FERRER INCODE, S.L.

Filing Date

Mar 7, 2016

Add to watchlist:

No watchlists yet
View on USPTO

LIPID INCODE Trademark

Serial Number: 79186567 • Registration: 5248111

LIPID INCODE is a trademark filed by FERRER INCODE, S.L. on March 7, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

FERRER INCODE, S.L. (10 trademarks)

Avenida Diagonal, 549
BARCELONA 08029 , ES

Entity Type: 03

GENINCODE U.K., LTD. (5 trademarks)

One St. Peters Square

Entity Type: 99

Trademark Details

Filing Date

March 7, 2016

Registration Date

July 25, 2017

Published for Opposition

May 9, 2017

Cancellation Date

February 9, 2024

Goods & Services

Diagnostic preparations for medical or veterinary purposes; products, reagents and indicators for medical diagnostics, namely, preparations, reagents and biological indicators for monitoring the diagnosis of Familiar Hypercholesterolemia as well as DLAL (Deficiency in Lysosomal Acid Lipase) for medical or veterinary purposes; Diagnostic agents for medical purposes, namely, diagnostic agents for pharmaceutical use; testing materials for medical use, namely, medical diagnostic reagents and assays for testing of body fluids; pharmaceutical and veterinary products, namely, pharmaceutical products for the treatment of Hypercholesterolemia; food supplements for humans or animals; nutraceutical products for therapeutic use and as a dietary supplement, namely, nutraceuticals for the treatment of Hypercholesterolemia and nutraceuticals for use as a dietary supplement; Plasters for medical purposes, namely, material for dressings; disinfectants

Medical services; diagnosis of diseases, namely, medical diagnosis of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; medical diagnostic services, testing and analysis, namely, medical diagnostic testing, monitoring and reporting services; genetic testing for diagnostics or treatments for medical purposes; medical information services provided on the Internet, namely, reporting of consumer authorized clinical testing results directly to the patient; Medical consultation and information services in the field of medical products, namely, providing information relating to diagnostic, prophylactic and treatment of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; medical, medicinal and pharmaceutical consultation services; medical advisory services; medical information services, namely, providing medical information; medical analyses for the diagnosis and treatment of people, namely, providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms and concerns, providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; Medical testing for diagnostic or treatment purposes, namely, medical testing relating to the diagnosis and treatment of people; Medical testing for diagnostic or treatment purposes, namely, medical laboratory services for the analysis of blood and saliva samples; Medical testing for diagnostic or treatment purposes, namely, medical laboratory services for the analysis of samples obtained from patients; Medical testing for diagnostic or treatment purposes, namely, medical laboratory services for the analysis of blood and saliva samples obtained from patients

Surgical, medical, dental and veterinary instruments and apparatus, namely, medical instruments and apparatus for use in a genetic diagnostic kit in the diagnosis of Familiar Hypercholesterolemia as well as DLAL (Deficiency in Lysosomal Acid Lipase) procedures; suture materials; instruments and apparatus for medical diagnostics, namely, apparatus for medical diagnostic testing in the fields of Familiar Hypercholesterolemia as well as DLAL (Deficiency in Lysosomal Acid Lipase); automatic analyzers for medical diagnostics, namely, medical diagnostic instruments for the analysis of body fluids; apparatus for diagnostic testing for medical purposes, namely, medical diagnostic apparatus for testing DNA; diagnostic test kits for detecting diseases, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in genetic body fluids testing; apparatus for analyzing DNA in biological samples for medical use; apparatus for collecting samples of body fluids, namely, medical specimen collection devices in the nature of glass slides, cups or bags for the collection of blood or saliva samples; Medical specimen bags for testing purposes, namely, bags for medical use in storing blood or saliva samples; Medical specimen bags for testing purposes, namely, bags for medical use in collecting blood or saliva samples; Sample preparation device for medical diagnostic uses, namely, sample preparation columns for medical use; containers for medical samples, namely, blood and saliva containers for medical purposes; devices for taking samples for medical use, namely, medical devices for obtaining body fluid samples; urine sample testing instruments for medical diagnostics in the nature of medical diagnostic apparatus for testing DNA; containers specially designed for transporting samples containing living human cells; holders for sample containers, namely, specimen cup holders; capillary tubes for samples

Medical and pharmaceutical research services; research and development services in the field of bacteriology; scientific research services for medical purposes in the field of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; chemical research and analysis; advisory services relating to pharmaceutical research; technical project study, namely, scientific study and research in the field of the prevention, treatment and management of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; medical research laboratory services; design and development of apparatus for medical diagnostics; computer-assisted diagnostic testing services, namely, diagnostic services in the field of Familiar Hypercholesterolemia, DLAL (Deficiency in Lysosomal Acid Lipase) and Cardiovascular Risks; Scientific laboratory services, namely, preparation of biological samples for research purposes; Scientific laboratory services, namely, preparation of biological samples for use in testing and analysis in research laboratories

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Nov 9, 2024 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Oct 24, 2024 INTS
INVALIDATION PROCESSED
Oct 24, 2024 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 10, 2024 INTR
CANCELLED SECTION 71
Feb 9, 2024 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Dec 24, 2022 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 25, 2022 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jul 9, 2021 NREP
CHANGE OF OWNER RECEIVED FROM IB
Dec 18, 2020 CHLD
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 20, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 20, 2019 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 24, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 3, 2017 FICS
FINAL DISPOSITION PROCESSED
Nov 3, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 25, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 25, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 9, 2017 NPUB
PUBLISHED FOR OPPOSITION
May 9, 2017 PUBO
NOTIFICATION PROCESSED BY IB
May 5, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 19, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 19, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 19, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 31, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 27, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 27, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 27, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 27, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 27, 2017 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 18, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 18, 2017 CRFA
ASSIGNED TO LIE
Feb 16, 2017 ALIE
NOTICE OF REVIVAL - E-MAILED
Feb 6, 2017 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 3, 2017 TROA
PETITION TO REVIVE-GRANTED
Feb 3, 2017 PETG
TEAS PETITION TO REVIVE RECEIVED
Feb 3, 2017 PROA
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jan 26, 2017 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 25, 2017 ABN2
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 3, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 3, 2016 REAP
REFUSAL PROCESSED BY IB
Jul 16, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 28, 2016 RFCS
REFUSAL PROCESSED BY MPU
Jun 28, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 28, 2016 RFCR
NON-FINAL ACTION WRITTEN
Jun 27, 2016 CNRT
ASSIGNED TO EXAMINER
Jun 20, 2016 DOCK
APPLICATION FILING RECEIPT MAILED
May 10, 2016 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 5, 2016 REPR